Identification

Name
Scopolamine
Accession Number
DB00747  (APRD00616)
Type
Small Molecule
Groups
Approved, Investigational
Description

An alkaloid from Solanaceae, especially Datura metel L. and Scopola carniolica. Scopolamine and its quaternary derivatives act as antimuscarinics like atropine, but may have more central nervous system effects. Among the many uses are as an anesthetic premedication, in urinary incontinence, in motion sickness, as an antispasmodic, and as a mydriatic and cycloplegic. [PubChem]

Structure
Thumb
Synonyms
  • (-)-hyoscine
  • (-)-scopolamine
  • (1S,3S,5R,6R,7S)-6,7-Epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate
  • 6-beta,7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate
  • 6,7-Epoxytropine tropate
  • alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
  • Hyoscine
  • scopine (-)-tropate
  • scopine (−)-tropate
  • Scopolamine hydrobromide
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Scopolamine Hydrobromide InjectionLiquid0.6 mgIntramuscular; Intravenous; SubcutaneousOmega Laboratories Ltd2008-07-08Not applicableCanada
Scopolamine Hydrobromide InjectionLiquid0.4 mgIntramuscular; Intravenous; SubcutaneousOmega Laboratories Ltd2008-05-31Not applicableCanada
Scopolamine Hydrobromide Injection USPSolution0.6 mgIntramuscular; Intravenous; SubcutaneousPfizer1981-12-31Not applicableCanada
Scopolamine Hydrobromide Injection USPSolution0.4 mgIntramuscular; Intravenous; SubcutaneousPfizer1981-12-31Not applicableCanada
Transderm ScopPatch, extended release1 mg/3dTransdermalPhysicians Total Care, Inc.2007-10-02Not applicableUs
Transderm ScopPatch, extended release1 mg/3dTransdermalBaxter Laboratories2003-01-01Not applicableUs
Transderm ScopPatch, extended release1 mg/3dTransdermalNovartis2007-10-02Not applicableUs
Transderm ScopPatch, extended release1 mg/3dTransdermalSandoz2016-12-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Scopolamine Trandermal SystemPatch, extended release1 mg/1TransdermalPerrigo New York Inc.2017-06-13Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Diban CapScopolamine (3.3 mcg) + Atropine Sulfate (9.7 mcg) + Attapulgite (300 mg) + Hyoscyamine sulfate (0.0519 mg) + Opium (12 mg) + Pectin (71.4 mg)CapsuleOralWyeth Ayerst Canada Inc.1998-02-182001-01-30Canada
Diban CapScopolamine (3.3 mcg) + Atropine Sulfate (9.7 mcg) + Attapulgite (300 mg) + Hyoscyamine sulfate (0.0519 mg) + Opium (12 mg) + Pectin (71.4 mg)CapsuleOralAyerst Laboratories1992-12-311999-04-12Canada
Donnagel LiqScopolamine (6.5 mcg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Kaolin (6 g) + Pectin (142.8 mg)LiquidOralWyeth Ayerst Canada Inc.1995-12-311997-08-14Canada
Donnagel LiqScopolamine (6.5 mcg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Kaolin (6 g) + Pectin (142.8 mg)LiquidOralAyerst Laboratories1993-12-311996-09-10Canada
Donnatal ElixirScopolamine (6.5 mcg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Phenobarbital (16.2 mg)ElixirOralAyerst Laboratories1991-12-311996-09-10Canada
Donnatal ElixirScopolamine (6.5 mcg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Phenobarbital (16.2 mg)ElixirOralWyeth Ayerst Canada Inc.1994-12-312001-01-16Canada
Donnatal ExtentabsScopolamine (0.0195 mg) + Atropine Sulfate (0.0582 mg) + Hyoscyamine sulfate (0.3111 mg) + Phenobarbital (48.6 mg)Tablet, extended releaseOralAyerst Laboratories1991-12-311996-09-10Canada
Donnatal Extentabs SrtScopolamine (0.0195 mg) + Atropine Sulfate (0.0582 mg) + Hyoscyamine sulfate (0.3111 mg) + Phenobarbital (48.6 mg)Tablet, extended releaseOralWyeth Ayerst Canada Inc.1994-12-312001-05-07Canada
Donnatal TabScopolamine (6.5 mcg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Phenobarbital (16.2 mg)TabletOralWyeth Ayerst Canada Inc.1994-12-312001-05-22Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Atenolol ScopolamineScopolamine (.25 mg/25.25mg) + Atenolol (25 mg/25.25mg)TabletBuccal; Oral; Sublingual; TransmucosalTPS2014-10-01Not applicableUs
Atenolol ScopolamineScopolamine (.5 mg/50.5mg) + Atenolol (50 mg/50.5mg)TabletOralTPS2014-10-01Not applicableUs
B-DonnaScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralWinder Laboratories, LLC2015-12-302016-03-11Us
Belladonna Alkaloids with PhenobarbitalScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralWest Ward Pharmaceutical1966-01-01Not applicableUs0143 114020170720 1564 4ev749
Belladonna Alkaloids with PhenobartbitalScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralRebel Distributors2004-08-31Not applicableUs
Belladonna Alkaloids with PhenobartbitalScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralLiberty Pharmaceuticals, Inc.2000-12-01Not applicableUs00143 1140 10 nlmimage10 bb045dd2
Belladonna Alkaloids with PhenobartbitalScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralLegacy Pharmaceutical Packaging2000-12-01Not applicableUs
Belladonna Alkaloids with PhenobartbitalScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralApace Packaging2000-12-012018-03-22Us
DonnatalScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralCarilion Materials Management2008-05-07Not applicableUs
DonnatalScopolamine (.0065 mg/5mL) + Atropine Sulfate (.0194 mg/5mL) + Hyoscyamine sulfate (.1037 mg/5mL) + Phenobarbital (16.2 mg/5mL)ElixirOralConcordia Pharmaceuticals, Inc1980-12-30Not applicableUs
International/Other Brands
Scopoderm / Transderm-Scop (Novartis)
Categories
UNII
DL48G20X8X
CAS number
51-34-3
Weight
Average: 303.3529
Monoisotopic: 303.147058165
Chemical Formula
C17H21NO4
InChI Key
STECJAGHUSJQJN-FWXGHANASA-N
InChI
InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13-,14+,15-,16+/m1/s1
IUPAC Name
(1R,2R,4S,5S,7R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0²,⁴]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate
SMILES
CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of excessive salivation, colicky abdominal pain, bradycardia, sialorrhoea, diverticulitis, irritable bowel syndrome and motion sickness.

Associated Conditions
Associated Therapies
Pharmacodynamics

Scopolamine is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine and acts by blocking the muscarinic acetylcholine receptors and is thus classified as an anticholinergic. Scopolamine has many uses including the prevention of motion sickness. It is not clear how Scopolamine prevents nausea and vomiting due to motion sickness. The vestibular part of the ear is very important for balance. When a person becomes disoriented due to motion, the vestibule sends a signal through nerves to the vomiting center in the brain, and vomiting occurs. Acetylcholine is a chemical that nerves use to transmit messages to each other. It is believe that Scopolamine prevents communication between the nerves of the vestibule and the vomiting center in the brain by blocking the action of acetylcholine. Scopolamine also may work directly on the vomiting center. Scopolamine must be taken before the onset of motion sickness to be effective.

Mechanism of action

Scopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center).

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
USucrase-isomaltase, intestinal
inhibitor
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M4
antagonist
Human
UMuscarinic acetylcholine receptor M5
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-4Not AvailableHuman
UNeuronal acetylcholine receptor subunit beta-2Not AvailableHuman
Absorption

Bioavailability is 10 - 50%

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Less than 10% of the total dose is excreted in the urine as parent and metabolites over 108 hours.

Half life

4.5 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Aceprometazine.Approved
AclidiniumScopolamine may increase the anticholinergic activities of Aclidinium.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Scopolamine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alfentanil.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Scopolamine.Approved, Illicit, Investigational
AmbenoniumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Ambenonium.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Scopolamine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Scopolamine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Scopolamine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Amperozide.Experimental
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Anisotropine Methylbromide.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Scopolamine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Scopolamine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Scopolamine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Azaperone.Investigational, Vet Approved
AzelastineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Scopolamine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine.Approved
BenperidolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Scopolamine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benzocaine.Approved, Investigational
BenzthiazideThe serum concentration of Benzthiazide can be increased when it is combined with Scopolamine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benzyl alcohol.Approved
BezitramideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Scopolamine is combined with Biperiden.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bornaprine.Experimental
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Scopolamine.Approved
Botulinum Toxin Type AScopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BScopolamine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved, Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Scopolamine.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Scopolamine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bupivacaine.Approved, Investigational
BuprenorphineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Scopolamine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Scopolamine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Scopolamine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Scopolamine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Butylscopolamine.Approved, Investigational, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Scopolamine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Scopolamine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Scopolamine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Scopolamine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Scopolamine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chloroprocaine.Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Scopolamine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Scopolamine.Approved
CimetropiumScopolamine may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Scopolamine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Scopolamine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Scopolamine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Scopolamine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Scopolamine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Scopolamine.Approved
CocaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Scopolamine.Approved
CoumaphosThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Coumaphos.Vet Approved
CyclizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Scopolamine.Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Scopolamine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclopentolate.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Scopolamine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Scopolamine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Darifenacin.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Demecarium.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Scopolamine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of sedation and somnolence can be increased when Scopolamine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Scopolamine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dexetimide.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Scopolamine.Approved, Illicit, Investigational, Vet Approved
DichlorvosThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dicyclomine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Scopolamine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Scopolamine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Diphenoxylate.Approved, Illicit
DipivefrinThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Dipivefrin.Approved
DistigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Distigmine.Experimental
DixyrazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dixyrazine.Experimental
DonepezilThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Scopolamine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Scopolamine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ecgonine.Experimental, Illicit
EchothiophateThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Echothiophate.Approved
EcopipamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Scopolamine.Approved
EdrophoniumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Scopolamine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Eltanolone.Investigational
EluxadolineScopolamine may increase the constipating activities of Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Emepronium.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Scopolamine.Approved, Investigational
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Scopolamine.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Scopolamine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Scopolamine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Scopolamine.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etanautine.Experimental
EthanolScopolamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Scopolamine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Scopolamine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etybenzatropine.Experimental
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Scopolamine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fexofenadine.Approved, Investigational
FlavoxateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flavoxate.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Scopolamine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Scopolamine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Scopolamine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Scopolamine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Scopolamine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gabapentin Enacarbil.Approved, Investigational
GalantamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Scopolamine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gepirone.Investigational
Ginkgo bilobaThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Scopolamine is combined with Glucagon recombinant.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Glutethimide.Approved, Illicit
GlycopyrroniumScopolamine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Scopolamine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Huperzine A.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine.Approved, Vet Approved
HydrocodoneScopolamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hyoscyamine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Scopolamine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Scopolamine.Approved
IndiplonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Indiplon.Investigational
IpidacrineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Ipidacrine.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Scopolamine.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Scopolamine.Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Scopolamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Scopolamine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Scopolamine.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lidocaine.Approved, Vet Approved
Lithium cationThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Scopolamine can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Scopolamine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Scopolamine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Scopolamine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Scopolamine.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Scopolamine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MalathionThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Malathion.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Maprotiline.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mazaticol.Experimental
MebicarThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Scopolamine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Scopolamine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Melperone.Approved, Investigational
MemantineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Memantine.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Scopolamine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Scopolamine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methantheline.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Scopolamine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Scopolamine.Approved
MethotrimeprazineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethscopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methscopolamine.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methsuximide.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methylscopolamine bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Scopolamine.Approved
MetyrosineScopolamine may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the anticholinergic activities of Scopolamine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Scopolamine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Scopolamine is combined with Milnacipran.Approved, Investigational
MinaprineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mirabegron.Approved
MirtazapineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Morphine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Scopolamine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nefazodone.Approved, Withdrawn
NeostigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nicomorphine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Scopolamine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Scopolamine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Scopolamine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Scopolamine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Opium.Approved, Illicit
OrphenadrineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Scopolamine is combined with Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Scopolamine.Approved
OxitropiumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxitropium.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxybuprocaine.Approved, Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxyphenonium.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Scopolamine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pancuronium.Approved
ParaldehydeScopolamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParaoxonThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Paraoxon.Experimental
ParoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Scopolamine.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Scopolamine.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
PerazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Scopolamine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Scopolamine.Approved
PethidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenglutarimide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Scopolamine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Scopolamine.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Physostigmine.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Scopolamine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pizotifen.Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Scopolamine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pomalidomide.Approved
Potassium ChlorideScopolamine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramipexoleScopolamine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintidePramlintide may increase the anticholinergic activities of Scopolamine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Scopolamine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Scopolamine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Scopolamine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Scopolamine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propantheline.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Proparacaine.Approved, Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Scopolamine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Scopolamine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Scopolamine.Approved
PSD502The risk or severity of adverse effects can be increased when Scopolamine is combined with PSD502.Investigational
PyridostigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Pyridostigmine.Approved, Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Scopolamine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Scopolamine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Scopolamine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Quinidine.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ramelteon.Approved, Investigational
RamosetronScopolamine may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Scopolamine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Scopolamine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Scopolamine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Scopolamine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ritanserin.Investigational
RivastigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Romifidine.Vet Approved
RopiniroleScopolamine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ropivacaine.Approved
RotigotineScopolamine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Scopolamine.Approved, Vet Approved
Secretin humanThe therapeutic efficacy of Human secretin can be decreased when used in combination with Scopolamine.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Scopolamine.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Scopolamine.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Solifenacin.Approved
StiripentolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sufentanil.Approved, Investigational
SulpirideScopolamine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sultopride.Experimental
SuvorexantScopolamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TacrineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TandospironeThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tasimelteon.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Scopolamine.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrodotoxin.Investigational
ThalidomideScopolamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Scopolamine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Scopolamine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tilidine.Experimental
TiotropiumScopolamine may increase the anticholinergic activities of Tiotropium.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Scopolamine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Scopolamine.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Scopolamine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tramadol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Scopolamine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tricaine methanesulfonate.Vet Approved
TrichlorfonThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Scopolamine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Scopolamine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Scopolamine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Scopolamine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tropicamide.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trospium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tubocurarine.Approved
TyrothricinThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Tyrothricin.Approved
UmeclidiniumScopolamine may increase the anticholinergic activities of Umeclidinium.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Scopolamine is combined with Valproic Acid.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vigabatrin.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Scopolamine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Scopolamine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Scopolamine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zolazepam.Vet Approved
ZolpidemScopolamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Scopolamine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Scopolamine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Yang Guodong, "Preparation and application of scopolamine and chlorpromazine as a drug-withdrawal agent." U.S. Patent US5543407, issued February, 1993.

US5543407
General References
  1. Putcha L, Cintron NM, Tsui J, Vanderploeg JM, Kramer WG: Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. Pharm Res. 1989 Jun;6(6):481-5. [PubMed:2762223]
External Links
Human Metabolome Database
HMDB0003573
KEGG Drug
D00138
KEGG Compound
C01851
PubChem Compound
3000322
PubChem Substance
46506966
ChemSpider
10194106
BindingDB
50015720
ChEBI
16794
ChEMBL
CHEMBL569713
Therapeutic Targets Database
DNC000757
PharmGKB
PA451308
IUPHAR
330
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Scopolamine
ATC Codes
S01FA02 — ScopolamineA04AD01 — ScopolamineA04AD51 — Scopolamine, combinationsN05CM05 — Scopolamine
AHFS Codes
  • 12:08.08 — Antimuscarinics Antispasmodics
FDA label
Download (686 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingPreventionAlzheimer's Disease (AD) / Dementias1
1Active Not RecruitingBasic ScienceHealthy Volunteers1
1Active Not RecruitingTreatmentAlzheimer's Disease (AD)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedDiagnosticUsing Copolamine Butylbromide in Probe-based Confocal Laser Endomicroscopy for Gastroendoscopy Examination1
1CompletedTreatmentAlzheimer's Disease (AD) / Memory Disturbances1
1CompletedTreatmentDementias1
1RecruitingBasic ScienceHealthy Volunteers1
1RecruitingTreatmentSocial Anxiety Disorder (SAD)1
1, 2CompletedTreatmentSialorrhea1
2CompletedPreventionMotion Sickness1
2Not Yet RecruitingTreatmentAnalgesia, Obstetrical1
2TerminatedTreatmentDepression, Bipolar / Unipolar Depression1
2, 3CompletedNot AvailableLabour Pain1
2, 3TerminatedTreatmentMotion Sickness1
4CompletedBasic ScienceHealthy Volunteers1
4Not Yet RecruitingTreatmentPatients1
4RecruitingOtherDrug Reaction1
4RecruitingPreventionLaparoscopic Sleeve Gastrectomy / Prophylaxis against postoperative nausea and vomiting1
4RecruitingPreventionNausea / Satisfaction / Vomiting1
4RecruitingTreatmentDepression1
4RecruitingTreatmentMajor Depressive Disorder (MDD)1
Not AvailableCompletedNot AvailableCholinergic Function1
Not AvailableCompletedNot AvailableRhytidoplasty1
Not AvailableCompletedDiagnosticAD1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableCompletedSupportive CareNausea / Vomiting1
Not AvailableCompletedTreatmentNausea / Vomiting1
Not AvailableRecruitingDiagnosticGastrointestinal Imaging With pCLE1
Not AvailableUnknown StatusPreventionSimulator Sickness1
Not AvailableUnknown StatusTreatmentDepression1
Not AvailableWithdrawnTreatmentMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
  • Boca pharmacal inc
  • Private formulations inc
Packagers
  • A. Aarons Inc.
  • Adamis Laboratories
  • Advanced Pharmaceutical Services Inc.
  • Alcon Laboratories
  • Alza Corp.
  • Amend
  • Apace Packaging
  • Apotheca Inc.
  • APP Pharmaceuticals
  • Aristos Pharmaceuticals
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Auriga Pharmaceuticals LLC
  • Bausch & Lomb Inc.
  • Baxter International Inc.
  • Boca Pharmacal
  • Bradley Pharmaceuticals Inc.
  • Breckenridge Pharmaceuticals
  • Bryant Ranch Prepack
  • Burel Pharmaceuticals Inc.
  • C.O. Truxton Inc.
  • Carwin Associates Inc.
  • Central Texas Community Health Centers
  • Contract Pharm
  • Cornerstone Pharmacy
  • Corvit Pharmaceuticals
  • Dexo LLC
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Excellium Pharmaceutical Inc.
  • H.J. Harkins Co. Inc.
  • Hawthorn Pharmaceuticals
  • Hope Pharmaceuticals
  • Irisys Inc.
  • Kaiser Foundation Hospital
  • Kenwood Labs
  • Kraft Pharmaceutical Co. Inc.
  • Kylemore Pharmaceuticals
  • Larken Laboratories Inc.
  • Liberty Pharmaceuticals
  • Llorens Pharmaceutical
  • Magna Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medi Rx Pharmaceutical Inc.
  • Mikart Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nexgen Pharma Inc.
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Patient First Corp.
  • PBM Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Provident Pharmaceuticals LLC
  • Qualitest
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • River's Edge Pharmaceuticals
  • Sandhills Packaging Inc.
  • SJ Pharmaceuticals LLC
  • Southwood Pharmaceuticals
  • Sovereign Pharmaceuticals Ltd.
  • Trigen Laboratories Inc.
  • United Research Laboratories Inc.
  • Veratex Corp.
  • Vintage Pharmaceuticals Inc.
  • Vision Pharma LLC
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
TabletBuccal; Oral; Sublingual; Transmucosal
CapsuleOral
LiquidOral
TabletOral
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral
Injection, solutionIntramuscular; Intravenous; Subcutaneous.4 mg/mL
LiquidIntramuscular; Intravenous; Subcutaneous0.4 mg
LiquidIntramuscular; Intravenous; Subcutaneous0.6 mg
SolutionIntramuscular; Intravenous; Subcutaneous0.4 mg
SolutionIntramuscular; Intravenous; Subcutaneous0.6 mg
Patch, extended releaseTransdermal1 mg/1
ElixirOral
Patch, extended releaseTransdermal1 mg/3d
Prices
Unit descriptionCostUnit
Oscion Cleanser 6% Lotion 340.2 gm Bottle88.56USD bottle
Oscion Cleanser 3% Lotion 340.2 gm Bottle85.69USD bottle
Isopto Hyoscine 0.25% Solution 5ml Bottle30.99USD bottle
Transderm-Scop 1.5 mg (1 Box Contains 4 Patches)14.87USD patch
Transderm-Scop 1.5 mg (1 Box Contains 10 Patches)12.04USD patch
Transderm-scop 1.5 mg/72hr12.01USD each
Scopolamine hbr crystals6.86USD g
Isopto hyoscine 0.25% drops5.59USD ml
Scopolamine 0.4 mg/ml vial5.4USD ml
Buscopan 20 mg/ml4.5USD ml
Pamine forte 5 mg tablet3.9USD tablet
Pamine 2.5 mg tablet2.66USD tablet
Methscopolamine Bromide 5 mg tablet2.17USD tablet
Methscopolamine brom 5 mg tablet2.09USD tablet
Methscopolamine Bromide 2.5 mg tablet1.67USD tablet
Methscopolamine brom 2.5 mg tablet1.61USD tablet
Scopace 0.4 mg tablet0.67USD tablet
Buscopan 10 mg Tablet0.34USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)59 °CPhysProp
water solubility1E+005 mg/LYALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.98SANGSTER (1994)
Caco2 permeability-4.93ADME Research, USCD
pKa7.75 (at 25 °C)SANGSTER,J (1994)
Predicted Properties
PropertyValueSource
Water Solubility6.61 mg/mLALOGPS
logP1.4ALOGPS
logP0.89ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)6.95ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area62.3 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity79.72 m3·mol-1ChemAxon
Polarizability31.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9615
Blood Brain Barrier+0.8218
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5174
P-glycoprotein inhibitor INon-inhibitor0.87
P-glycoprotein inhibitor IINon-inhibitor0.8623
Renal organic cation transporterInhibitor0.531
CYP450 2C9 substrateNon-substrate0.7002
CYP450 2D6 substrateNon-substrate0.7296
CYP450 3A4 substrateSubstrate0.5253
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.927
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9581
BiodegradationNot ready biodegradable0.9073
Rat acute toxicity2.0907 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9378
hERG inhibition (predictor II)Non-inhibitor0.9167
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0009000000-9733effdc3262b114ed6
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0809000000-a686e4c768aedb57cf8e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-1901000000-f66f538c7db471e86fd5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-3900000000-5eedeba4bedea55de9ad
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udr-7900000000-1309364bbca3810a6afa
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000i-0900000000-1c1d2f52fb7a5d745e1e

Taxonomy

Description
This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Hydroxy acids and derivatives
Sub Class
Beta hydroxy acids and derivatives
Direct Parent
Beta hydroxy acids and derivatives
Alternative Parents
Piperidines / Benzene and substituted derivatives / Morpholines / N-alkylpyrrolidines / Trialkylamines / Amino acids and derivatives / Carboxylic acid esters / Azacyclic compounds / Oxacyclic compounds / Dialkyl ethers
show 7 more
Substituents
Beta-hydroxy acid / Monocyclic benzene moiety / Morpholine / Oxazinane / Piperidine / N-alkylpyrrolidine / Benzenoid / Pyrrolidine / Amino acid or derivatives / Carboxylic acid ester
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, epoxide, propanoate ester, tropane alkaloid (CHEBI:16794)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Murasaki O, Kaibara M, Nagase Y, Mitarai S, Doi Y, Sumikawa K, Taniyama K: Site of action of the general anesthetic propofol in muscarinic M1 receptor-mediated signal transduction. J Pharmacol Exp Ther. 2003 Dec;307(3):995-1000. Epub 2003 Oct 8. [PubMed:14534362]
  2. Klinkenberg I, Blokland A: The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev. 2010 Jul;34(8):1307-50. doi: 10.1016/j.neubiorev.2010.04.001. Epub 2010 Apr 14. [PubMed:20398692]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sucrose alpha-glucosidase activity
Specific Function
Plays an important role in the final stage of carbohydrate digestion. Isomaltase activity is specific for both alpha-1,4- and alpha-1,6-oligosaccharides.
Gene Name
SI
Uniprot ID
P14410
Uniprot Name
Sucrase-isomaltase, intestinal
Molecular Weight
209451.49 Da
References
  1. Minai-Tehrani D, Fooladi N, Minoui S, Sobhani-Damavandifar Z, Aavani T, Heydarzadeh S, Attar F, Ghaffari M, Nazem H: Structural changes and inhibition of sucrase after binding of scopolamine. Eur J Pharmacol. 2010 Jun 10;635(1-3):23-6. doi: 10.1016/j.ejphar.2010.02.040. Epub 2010 Mar 15. [PubMed:20230815]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Johnson DE, Nedza FM, Spracklin DK, Ward KM, Schmidt AW, Iredale PA, Godek DM, Rollema H: The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release. Eur J Pharmacol. 2005 Jan 4;506(3):209-19. Epub 2004 Dec 15. [PubMed:15627430]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR: The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem. 2007 Nov;3(6):543-5. [PubMed:18045203]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR: The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem. 2007 Nov;3(6):543-5. [PubMed:18045203]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR: The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem. 2007 Nov;3(6):543-5. [PubMed:18045203]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Smulders CJ, Zwart R, Bermudez I, van Kleef RG, Groot-Kormelink PJ, Vijverberg HP: Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol. 2005 Feb 21;509(2-3):97-108. [PubMed:15733544]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNB2
Uniprot ID
P17787
Uniprot Name
Neuronal acetylcholine receptor subunit beta-2
Molecular Weight
57018.575 Da
References
  1. Smulders CJ, Zwart R, Bermudez I, van Kleef RG, Groot-Kormelink PJ, Vijverberg HP: Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol. 2005 Feb 21;509(2-3):97-108. [PubMed:15733544]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]

Drug created on June 13, 2005 07:24 / Updated on July 20, 2018 19:27